CombiMatrix to Present Large-Scale Study Indicating the Severity of Genomic Abnormalities Decreases from Conception to Childh...
20 January 2017 - 10:00PM
CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular
diagnostics company specializing in DNA-based reproductive health
and pediatric testing services, announces that results from a
first-of-its-kind study spanning preimplantation genetic screening
of embryos to microarray analysis for pediatric neurodevelopmental
disorders will be presented on January 21, 2017, at the 2nd World
Congress of Recurrent Pregnancy Loss in Cannes, France.
Trilochan Sahoo, M.D., FACMG, CombiMatrix Vice President of
Clinical Affairs and Director of Cytogenetics, will discuss the
results from more than 29,000 samples indicating that genomic
alterations decrease in frequency and severity from conception
through childhood.
This ambitious study was aimed at exploring and
cataloging the variety, diversity and evolution of genomic
abnormalities with adverse effects on human conception, pregnancy
and childhood growth and development. It included an
exhaustive analysis of CombiMatrix’s exclusive data generated over
the last few years. An abstract of the study, “Unraveling the
Diverse Landscape of Genomic Abnormalities from Conception to
Childhood,” is available at
http://combimatrix.com/providers/educational-references. The
abstract reviews outcomes from preimplantation genetic screening
(PGS) of 3,349 embryos and chromosomal microarray analysis testing
of 8,118 pregnancy loss samples, 3,245 prenatal samples, 1,351
neonatal samples and 7,047 pediatric samples. A spectrum of
unbalanced genomic abnormalities was detected in each sample
type. Key findings include:
- Embryo or early pregnancy loss samples showed the highest
abnormality rates and a predictable correlation between the
severity of chromosomal abnormalities, primarily aneuploidies, with
unsuccessful implantation or progression to viable
pregnancy.
- Prenatal and neonatal samples showed that the frequency of
significant genomic alterations correlated with the incidence of
significant physical and developmental abnormalities, but were not
necessarily incompatible with life.
- Pediatric samples were predominantly deletions and duplications
rather than aneuploidy and with less drastic adverse effects.
“The knowledge that genomic rearrangements are
an important cause of genetic disease provided a rationale for
conducting this first comprehensive study analyzing correlations
between cytogenomic abnormalities and adverse effects on human
growth and development from conception into childhood,” said Dr.
Sahoo. “The results were highly informative in revealing an
evolution of genomic alterations of decreasing severity as human
growth progresses from conception through childhood. Importantly,
we now have clear evidence that allows us to appreciate the
delicate balances that the cellular machinery must maintain for
normal genomic content and stability.”
“As more data are collected and analyzed on
genomic abnormalities and their impact on early life, we gain a
better understanding of the importance of genomic testing at
different stages of development,” said Mark McDonough, CombiMatrix
President and CEO. “This study is yet another example of
CombiMatrix’s commitment to driving scientific advancement as a
market leader in recurrent pregnancy loss and reproductive health
diagnostic testing. Our findings provide valuable information to
physicians and their patients when deciding to employ molecular
diagnostic testing from embryo preimplantation to early
childhood.”
About CombiMatrix
Corporation
CombiMatrix Corporation provides best-in-class
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in pre-implantation genetic diagnostics and screening,
prenatal diagnosis, miscarriage analysis and pediatric
developmental disorders, offering DNA-based testing for the
detection of genetic abnormalities beyond what can be identified
through traditional methodologies. Our testing focuses on advanced
technologies, including single nucleotide polymorphism (“SNP”)
chromosomal microarray analysis (“CMA”), next generation sequencing
(“NGS”), fluorescent in situ hybridization (“FISH”) and high
resolution karyotyping. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," “approximates,”
"expects," "intends," "plans," "goal," "predicts," "believes,"
"seeks," "estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, statements regarding projected results of operations,
including projected cash flow-positive operating results,
management's future business, operational and strategic plans,
recruiting efforts and test menu expansion. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties referred
to above include, but are not limited to: our estimates of total
market sizes for the tests that we offer; our ability to grow
revenue and improve gross margin; delays in achieving cash
flow-positive operating results; the risk that test volumes and
reimbursements level off or decline; the risk that payors decide to
not cover our tests or to reduce the amounts they are willing to
pay for our tests; the risk that we will not be able to grow our
business as quickly as we need to; the inability to raise capital;
the loss of members of our sales force; our ability to successfully
expand the base of our customers, add to the menu of our diagnostic
tests, develop and introduce new tests and related reports, expand
and improve our current suite of diagnostic services, optimize the
reimbursements received for our molecular testing services, and
increase operating margins by improving overall productivity and
expanding sales volumes; our ability to successfully accelerate
sales, steadily increase the size of our customer rosters in all of
our genetic testing markets; our ability to attract and retain
a qualified sales force in wider geographies; our ability to ramp
production from our sales; rapid technological change in our
markets; changes in demand for our future services; legislative,
regulatory and competitive developments; general economic
conditions; and various other factors. Further information on
potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason, except as
required by law.
Company
Contact: |
|
|
|
|
|
|
|
|
|
|
|
Investor
Contact: |
Mark
McDonough |
|
|
|
|
|
|
|
|
|
|
|
LHA |
President & CEO, CombiMatrix Corporation |
|
|
|
|
|
|
|
|
|
|
|
Jody
Cain |
(949)
753-0624 |
|
|
|
|
|
|
|
|
|
|
|
(310)
691-7100 |
|
|
|
|
|
|
|
|
|
|
|
|
jcain@lhai.com |
|
|
|
|
|
|
|
|
|
|
|
|
|
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Apr 2024 to May 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From May 2023 to May 2024